BioNTech SE (NASDAQ:BNTX) Short Interest Down 16.2% in October

BioNTech SE (NASDAQ:BNTX) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 2,020,000 shares, a decrease of 16.2% from the October 15th total of 2,410,000 shares. Based on an average trading volume of 997,700 shares, the short-interest ratio is currently 2.0 days.

BioNTech Price Performance

Shares of BioNTech stock traded down $3.84 during midday trading on Friday, hitting $99.72. 3,377,161 shares of the company were exchanged, compared to its average volume of 805,347. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market cap of $23.91 billion, a P/E ratio of -47.49 and a beta of 0.26. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a 50 day simple moving average of $113.54 and a 200-day simple moving average of $97.18.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the previous year, the company posted $0.73 EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. Research analysts forecast that BioNTech will post -3.47 earnings per share for the current year.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of research analyst reports. HC Wainwright raised their target price on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a report on Monday, October 7th. JPMorgan Chase & Co. lowered their target price on BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a report on Monday, November 4th. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. HSBC raised their target price on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Finally, TD Cowen decreased their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.54.

Institutional Investors Weigh In On BioNTech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Covestor Ltd grew its stake in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. GAMMA Investing LLC boosted its position in BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after buying an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the last quarter. Planning Capital Management Corp increased its stake in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares during the period. Finally, Blue Trust Inc. raised its position in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.